Cue Biopharma Executes 1-for-30 Reverse Split to Maintain Nasdaq Listing
Event summary
- Cue Biopharma (CUE) approved and will implement a 1-for-30 reverse stock split, effective April 23, 2026.
- The split aims to increase the per-share market price to regain compliance with Nasdaq’s minimum bid price requirement.
- The reverse split will reduce the number of outstanding shares from approximately 97.7 million to roughly 3.3 million.
- Shareholders approved the split at the company’s Annual Meeting on April 13, 2026.
- Existing stock options, warrants, and equity incentive plans will be adjusted proportionally.
The big picture
The reverse stock split is a common, albeit often temporary, measure taken by companies facing delisting threats. It signals underlying financial distress and a lack of investor confidence, despite Cue Biopharma’s innovative Immuno-STAT platform and lead asset CUE-401. While the split provides a short-term reprieve, the company’s long-term viability depends on demonstrating clinical and commercial success.
What we're watching
- Listing Stability
- The success of the reverse split hinges on whether it sustainably elevates the share price above Nasdaq’s minimum requirement, avoiding further delisting risks.
- Investor Sentiment
- How existing and potential investors react to the split will be crucial; a negative response could exacerbate the underlying issues driving the low share price.
- Clinical Progress
- The company’s ability to demonstrate meaningful clinical progress with CUE-401 and other pipeline assets will ultimately be the primary driver of long-term value, overshadowing the effects of the reverse split.
Related topics